The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.
The results, published in the European Heart Journal and presented at the European Society of Cardiology Congress, opens the way to new therapies for patients with genetic heart diseases
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), together with cardiologists from Hospital Universitario Puerta de Hierro and the Spanish cardiovascular disease research network (CIBERCV), report that the new discovery makes it possible to identify high-risk patients early and refer them sooner to specialized heart failure units
The results, published in JACC, suggest that these factors could be used to predict the risk of developing dilated cardiomyopathy and adapt strategies for patient care and disease detection in genetic carriers of the disease
